Document Detail


Characterization of a naphthalene derivative inhibitor of retroviral integrases.
MedLine Citation:
PMID:  15018700     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The retroviral integrase protein (IN) is essential for virus replication and, therefore, an attractive target for the development of inhibitors to treat human immunodeficiency virus (HIV) infection. Diverse classes of compounds that are active against this protein have been discovered using in vitro assays. Here we describe the synthesis of a novel compound, 3,8-dibromo-7-amino-4-hydroxy-2-naphthalenesulfonic acid (2BrNSA), which inhibits the in vitro activities of the full-length HIV-1 and avian sarcoma virus (ASV) integrases, and the isolated catalytic core fragment of the ASV protein (residues 52-207). The compound also inhibits retroviral reverse transcriptase in vitro, but the IC(50) for the HIV-1 enzyme is almost two orders of magnitude higher than for HIV-1 integrase. The inhibitor was found to be active in cell culture, preventing reporter gene transduction of HeLa cells by both ASV and HIV-1 vectors. Neither viral attachment nor uptake into cells appeared to be affected in these transfections, whereas accumulation of vector DNA and its joining to host DNA were both drastically reduced in the presence of the inhibitor. Propagation of two different strains of replication-competent HIV-1 in human peripheral blood mononuclear cells (PBMCs) was also reduced by the inhibitor, allowing survival of a substantial number of cells in the treated cultures. Based on these and other results we speculate that binding of 2BrNSA to integrase in infected cells interferes not only with its catalytic activity but also with critical interactions that are required for the formation or function of the reverse transcriptase complex. Its activity in cell culture suggests that this inhibitor may provide a valuable new lead for further development of drugs that target early steps in the HIV life cycle.
Authors:
R Daniel; C B Myers; J Kulkosky; K Taganov; J G Greger; G Merkel; I T Weber; R W Harrison; A M Skalka
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  AIDS research and human retroviruses     Volume:  20     ISSN:  0889-2229     ISO Abbreviation:  AIDS Res. Hum. Retroviruses     Publication Date:  2004 Feb 
Date Detail:
Created Date:  2004-03-15     Completed Date:  2004-05-19     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  8709376     Medline TA:  AIDS Res Hum Retroviruses     Country:  United States    
Other Details:
Languages:  eng     Pagination:  135-44     Citation Subset:  IM; X    
Affiliation:
Fox Chase Cancer Center, Institute for Cancer Research, Philadelphia, Pennsylvania 19111-2497, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Avian Sarcoma Viruses / drug effects,  enzymology,  genetics
Base Sequence
DNA, Viral / genetics
HIV Integrase Inhibitors / chemistry,  pharmacology*
HIV-1 / drug effects*,  enzymology*,  genetics
Hela Cells
Humans
Integrase Inhibitors / chemistry,  pharmacology
Naphthalenes / chemistry,  pharmacology*
Transduction, Genetic
Virus Replication / drug effects
Grant Support
ID/Acronym/Agency:
AI40385/AI/NIAID NIH HHS; CA06927/CA/NCI NIH HHS; CA71515/CA/NCI NIH HHS; GM62920/GM/NIGMS NIH HHS
Chemical
Reg. No./Substance:
0/DNA, Viral; 0/HIV Integrase Inhibitors; 0/Integrase Inhibitors; 0/Naphthalenes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Peripheral T cell lymphoma with cytotoxic phenotype: an emerging disease in HIV-infected patients?
Next Document:  A potent anti-HIV immunotoxin blocks spreading infection by primary HIV type 1 isolates in multiple ...